Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Consensus Target Price from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have earned an average rating of “Hold” from the ten ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $9.33.

FULC has been the topic of a number of research analyst reports. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. HC Wainwright reissued a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th.

Fulcrum Therapeutics Stock Up 1.0 %

Shares of Fulcrum Therapeutics stock opened at $4.10 on Thursday. Fulcrum Therapeutics has a 52-week low of $2.86 and a 52-week high of $13.70. The company’s 50-day simple moving average is $4.02 and its 200-day simple moving average is $5.49. The firm has a market cap of $221.15 million, a price-to-earnings ratio of -13.23 and a beta of 2.06.

Institutional Investors Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. National Bank of Canada FI increased its holdings in Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after buying an additional 4,000 shares during the last quarter. Profund Advisors LLC bought a new position in Fulcrum Therapeutics during the second quarter worth $68,000. China Universal Asset Management Co. Ltd. raised its position in shares of Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after buying an additional 4,701 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Fulcrum Therapeutics in the 2nd quarter valued at approximately $82,000. Finally, Walleye Capital LLC acquired a new position in shares of Fulcrum Therapeutics in the third quarter valued at $59,000. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.